Sasha
Forum Chief
- 7,667
- 11
- 0
I've recently been curious about Res-Q-Pods, so decided to do some reading. Anyone familiar with them? Does your service use them? Do you feel they successfully contribute to a ROSC? Do you feel they're a pointless waste of money? I've heard, anecdotally, that they are expensive. The website claims it improves circulation to the heart and brain.
Here is something from the website explaining how it works.
So, is it kind of like a reverse PEEP, in a way?
And a study showing improved results with the use of an ITD device.
Full study can be found Here
Here is something from the website explaining how it works.
The ResQPOD prevents unnecessary air from entering the chest during CPR. As the chest wall recoils, the vacuum (negative pressure) in the thorax is greater. This enhanced vacuum pulls more blood back to the heart, doubling blood flow during CPR. Studies have shown that this mechanism increases cardiac output, blood pressure and survival rates. Patient ventilation and exhalation are not restricted in any way.
So, is it kind of like a reverse PEEP, in a way?
And a study showing improved results with the use of an ITD device.
Full study can be found Here
Methods:
ITD use was implemented by the Staffordshire Ambulance Trust, which treats 1600 cardiac arrests per year with 90 advanced life support (ALS) units and an average response time of 6.3min. During training, rescuers learned to use the ventilation timing lights to discourage hyperventilation. Rescuers applied the device after tracheal intubation. They were trained to allow the chest to recoil fully after each compression. Prospective ITD use in adults receiving conventional manual CPR for non-traumatic cardiac arrest was compared to matched historical controls receiving conventional manual CPR without inspiratory impedance. All received similar ALS care. The primary endpoint was admission to the emergency department (ED) alive following cardiac arrest. Chi-square, Fisher's exact and Kolmogorov–Smirnov tests were used for statistical analyses.
Results:
Survival (alive upon ED admission) in all patients receiving an ITD (61/181 [34%]) improved by 50% compared to historical controls (180/808 [22%]) (P<0.01). Survival in patients presenting in asystole tripled in the group receiving an ITD (26/76 [34%]) compared with historical controls (39/351 [11%]) (P=0.001). There were no significant adverse events.